MannKind Corporation (NASDAQ:MNKD) shares are trending on social media Monday. Here's a look at what's going on.
What To Know:
The company announced initial meal challenge data from INHALE-3, a Phase 4 clinical trial evaluating inhaled insulin (plus basal) versus the current standard of care.
“One of the challenges of inhaled insulin adoption has been under-dosing when converting from injectable insulin, which causes patients to experience hyperglycemia,” said Dr. Kevin Kaiserman, senior vice president of clinical development and medical affairs for MannKind Corporation.
“In this large, randomized trial utilizing more appropriate dose conversion, we are excited to see meal challenge results support the safety and efficacy of inhaled insulin from the start.”
On Feb. 27, MannKind reported fourth-quarter earnings of 2 cents per share and quarterly sales of $58.47 million ...